Evelo Biosciences, Inc.
EVLO
$0.00
$0.00-20.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.89M | 4.72M | 7.04M | 5.00M | 7.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.39M | 17.46M | 24.90M | 21.09M | 29.05M |
| Operating Income | -10.39M | -17.46M | -24.90M | -21.09M | -29.05M |
| Income Before Tax | -12.38M | -20.87M | -25.20M | -23.00M | -30.46M |
| Income Tax Expenses | -17.00K | 233.00K | 145.00K | 544.00K | 107.00K |
| Earnings from Continuing Operations | -12.36M | -21.10M | -25.34M | -23.54M | -30.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.36M | -21.10M | -25.34M | -23.54M | -30.56M |
| EBIT | -10.39M | -17.46M | -24.90M | -21.09M | -29.05M |
| EBITDA | -10.22M | -17.03M | -24.46M | -20.56M | -28.57M |
| EPS Basic | -0.71 | -3.78 | -4.57 | -4.29 | -5.66 |
| Normalized Basic EPS | -0.42 | -2.10 | -2.84 | -2.56 | -3.52 |
| EPS Diluted | -0.71 | -3.78 | -4.57 | -4.29 | -5.66 |
| Normalized Diluted EPS | -0.42 | -2.10 | -2.84 | -2.56 | -3.52 |
| Average Basic Shares Outstanding | 17.38M | 5.58M | 5.55M | 5.49M | 5.40M |
| Average Diluted Shares Outstanding | 17.38M | 5.58M | 5.55M | 5.49M | 5.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |